

International Multispeciality Journal of Health

ISSN: 2395-6291



www.imjhealth.org

Volume-10, Issue-3, March 2024

Preface

We would like to present, with great pleasure, the inaugural volume-10, Issue-3, March 2024, of a scholarly journal, *International Multispeciality Journal of Health*. This journal is part of the AD Publications series *in the field of Medical, Health and Pharmaceutical Research Development*, and is devoted to the gamut of Medical, Health and Pharmaceutical issues, from theoretical aspects to application-dependent studies and the validation of emerging technologies.

This journal was envisioned and founded to represent the growing needs of Medical, Health and Pharmaceutical as an emerging and increasingly vital field, now widely recognized as an integral part of scientific and technical statistics investigations. Its mission is to become a voice of the Medical, Health and Pharmaceutical community, addressing researchers and practitioners in below areas

Clinical Specialty and Super-specialty Medical Science:

It includes articles related to General Medicine, General Surgery, Gynecology & Obstetrics, Pediatrics, Anesthesia, Ophthalmology, Orthopedics, Otorhinolaryngology (ENT), Physical Medicine & Rehabilitation, Dermatology & Venereology, Psychiatry, Radio Diagnosis, Cardiology Medicine, Cardiothoracic Surgery, Neurology Medicine, Neurosurgery, Pediatric Surgery, Plastic Surgery, Gastroenterology, Gastrointestinal Surgery, Pulmonary Medicine, Immunology & Immunogenetics, Transfusion Medicine (Blood Bank), Hematology, Biomedical Engineering, Biophysics, Biostatistics, Biotechnology, Health Administration, Health Planning and Management, Hospital Management, Nephrology, Urology, Endocrinology, Reproductive Biology, Radiotherapy, Oncology and Geriatric Medicine.

Para-clinical Medical Science:

It includes articles related to Pathology, Microbiology, Forensic Medicine and Toxicology, Community Medicine and Pharmacology.

Basic Medical Science:

It includes articles related to Anatomy, Physiology and Biochemistry.

Spiritual Health Science:

It includes articles related to Yoga, Meditation, Pranayam and Chakra-healing.

Each article in this issue provides an example of a concrete industrial application or a case study of the presented methodology to amplify the impact of the contribution. We are very thankful to everybody within

that community who supported the idea of creating a new Research with *IMJ Health*. We are certain that this issue will be followed by many others, reporting new developments in the Medical, Health and Pharmaceutical Research Science field. This issue would not have been possible without the great support of the Reviewer, Editorial Board members and also with our Advisory Board Members, and we would like to express our sincere thanks to all of them. We would also like to express our gratitude to the editorial staff of AD Publications, who supported us at every stage of the project. It is our hope that this fine collection of articles will be a valuable resource for *IMJ Health* readers and will stimulate further research into the vibrant area of Medical, Health and Pharmaceutical Research.



Dr. Kusum Gaur
(Chief Editor)



Mr. Mukesh Arora
(Managing Editor)

Board Members

Dr. Kusum Gaur (Editor-in-chief)

Dr. Kusum Gaur working as professor Community Medicine and member of Research Review Board of Sawai Man Singh Medical College, Jaipur (Raj) India.

She has awarded with WHO Fellowship for IEC at Bangkok. She has done management course from NIHFW. She has published and present many research paper in India as well as abroad in the field of community medicine and medical education. She has developed Socio-economic Status Scale (Gaur's SES) and Spiritual Health Assessment Scale (SHAS). She is 1st author of a book entitled " Community Medicine: Practical Guide and Logbook.

Research Area: Community Medicine, Biostatics, Epidemiology, Health and Hospital Management and Spiritual Health.

Mukesh Arora (Managing Editor)

BE (Electronics & Communication), M.Tech (Digital Communication), currently serving as Assistant Professor in the Department of ECE.

Dr. AMER A. TAQA

Dr. AMER A. TAQA is Professor and Head in Dental Basic Science Mosul University, Mosul, IRAQ. He has been registrar of department of Dental Basic Science Mosul University, Mosul, IRAQ. He has published about 100 of research papers and out of that 50 were of international level. He has awarded many times for scientific researches by Government. He has been member of many examination committees and also is a Member in Iraqi Scientific Staff. He has been working as Editor - reviewer in many journals.

Research Area: Dental Science.

Dr. I.D. Gupta

Dr. I. D. Gupta is Professor Psychiatry and working as additional Principal and Dean of student welfare in SMS Medical College, Jaipur.

He is recipient of Prof. Shiv Gautam oration award by Indian Psychiatric Society. He has done training in YMRS at Monte Carlo and BPRS at Singapore. He has been President Indian Psychiatric Society, Rajasthan State Branch. He is author of "Psycho Somatic Disorder" chapter in 1st edition post graduate text book of Psychiatry by Vyas and Ahuja. He has also worked with National Mental Health Programme and has a lot of publication.

Research Area: Community Mental Health, Psycho somatic and liaison Psychiatry.

Dr. Lokendra Sharma

Dr. Lokendra Sharma is Associate Professor Pharmacology and working as Nodal officer of SMS Medical College, Jaipur.

He is recipient of WHO Fellowship award on Poison Patient Management at Vietnam. He is resource faculty for Experimental Toxicology and Basic Course for Medical Education. He is presented and published a lot of research articles at national and international level.

Research Area: PHARMACOLOGY

Dr. Anuradha Yadav

Dr. Anuradha Yadav is working as Professor Physiology, SMS Medical College, Jaipur (Rajsthan) India. She is a popular medical teacher and research scholar who had many publications in indexed journals.

Research Area: CVS & CNS physiology, Medical Education and Spiritual Health.

Dr. Rajeev Yadav

Dr. Rajeev Yadav is working as Associate Professor Community Medicine, SMS Medical College, Jaipur (Rajsthan) India. He is member of Research Review Board of the Institute.

He has authored a book entitled "Community Medicine: Practcal Guide and Logbook".

Research Area: His area of Interest are Epidemiology, Biostatistics and Spiritual Health.

Prof. Dillip Kumar Parida

Professor and Head in the Department of Oncology, AIIMS, Bhubaneswar.

He has done the Professional Training in Japan (Osaka University, NIBI, AHCC Research Association, Hyogo Ion Beam Center), ESTRO Fellowship in Denmark and India(AIIMS Delhi, BARC Mumbai, SCB Medical College-Cuttak, MKCG Medical College-Berhampur).

Research Area: Brachytherapy, Total Skin Electron Irradiation, Palliative Radiotherapy, Stereotactic & Conformal radiotherapy, Radiation Cell Biology, Cancer Genetics.

Dr. Praveen Mathur

Dr. Praveen Mathur is working as Professor- Pediatric Surgery and is recipient of Commonwealth Fellowship in Pediatric Laparoscopy from Uk and fellowship award in minimal access Surgery (FMAS). He has done Clinical observer ship in the Department of Pediatric Surgery, Johns Hopkins University, Baltimore, USA. (2008). He has presented and published a number of research articles at national and international level. He is reviewer of prestigious Journal of Pediatric Surgery (JPS) and World Journal of Gastroenterology, Journal of neonatal Surgery (JNS).

Research Area: Pediatric Surgery & Laparoscopy.

Dr. Lokendra Sharma

Dr. Lokendra Sharma is Associate Professor Pharmacology and working as Nodal officer of SMS Medical College, Jaipur.

He is recipient of WHO Fellowship award on Poison Patient Management at Vietnam. He is resource faculty for Experimental Toxicology and Basic Course for Medical Education. He is presented and published a lot of research articles at national and international level.

Research Area: PHARMACOLOGY.

Dr Rajeev Sharma (MS; FMAS; FIMSA;FCLS)

He is working as Professor, Department of Surgery, Government Medical College, Chandigarh, India. He has done FMAS, FIMSA and FCLS along with MS (Gen Surgery).

He has about 50 international and national publications to his credit. He has held various positions in the Association of Minimal Access Surgeons of India (AMASI) from time to time. He has also acted as instructor of various AMASI skill courses held at different places in India. He has established Surgical Technique learning centre at GMCH Chandigarh for imparting training to the budding surgeons in the field of minimal access surgery. He is also the reviewer in the subject in various journals.

Research Area: Minimal Access Surgery.

Dr Anshu Sharma (MS ANATOMY)

She is Presently working as assistant professor in the department of Anatomy, GMCH, Chandigarh. She has many publications in various national and international journals. She is executive member of Anatomical Society of India (ASI) and North Chapter of ASI. She is also a member of editorial board of Journal of Medical College Chandigarh.

Research Area: Congenital Malformation, Developmental Anatomy.

Dr. Rajeev Yadav

Dr. Rajeev Yadav is working as Associate Professor Community Medicine, SMS Medical College, Jaipur (Rajsthan) India. He is member of Research Review Board of the Institute.

He has authored a book entitled "Community Medicine: Practical Guide and Logbook".

Research Area: His areas of Interest are Epidemiology, Biostatistics and Spiritual Health.

Dr. Dilip Ramlakhyani

Dr. Dilip Ramlakhyani working as Associate professor Pathology and member of IT Committee of Sawai Man Singh Medical College, Jaipur (Raj) India. He has published many articles in indexed journals.

Dr. Virendra Singh

Dr. Virendra Singh worked as Supernatant and head of department of Pulmonary Medicine, SMS Medical College, Jaipur (Rajsthan) India.

He has gone abroad for many training courses and to present research papers. He had been chairman of Research Review Board of SMS Medical College, Jaipur. He is a great research scholar and had published book related to his faculty and had many publications in indexed journals.

Dr. Mahesh Sharma

Dr. Mahesh Sharma is a Principle specialist General Surgery in Rajasthan State Government, India. He has been PMO of district hospitals for more than 15 years. He has gone abroad as observer of many of training related to his speciality. He has published and present many research paper in India as well as abroad.

He has developed Spiritual Health Assessment Scale (SHAS) with Dr. Kusum Gaur.

Research Area: General Surgery, Health and Hospital management and Spiritual Health.

Dr. Ravindra Manohar

Professor Community Medicine, working as head of department of PSM, SMS Medical College, Jaipur (Rajsthan) India.

Previously he has worked in BP Kiorala Institute of Medical Sciences, Nepal. He has visited CDC Atlántica for a Statistical workshop. He has been convener of MBBS and PG exams. He is a research scholar and had many publications in indexed journals.



Dr. Praveen Mathur

Dr. Praveen Mathur is working as Professor- Pediatric Surgery and is recipient of Commonwealth Fellowship in Pediatric Laparoscopy from Uk and fellowship award in minimal access Surgery (FMAS). He has done Clinical observer ship in the Department of Pediatric Surgery, Johns Hopkins University, Baltimore, USA. (2008). He has presented and published a number of research articles at national and international level. He is reviewer of prestigious Journal of Pediatric Surgery (JPS) and World Journal of Gastroenterology, Journal of neonatal Surgery (JNS).

Research Area: Pediatric Surgery & Laparoscopy.

Table of Contents

Volume-10, Issue-3, March 2024

S.No	Title	Page No.
1	<p>Management Approach to a Patient with Borderline Personality Disorder, Trichotillomania, and Alcohol Dependence Syndrome: Use of Endoxifen</p> <p>Authors: Yogesh Avinash Kulkarni</p> <p> DOI: https://dx.doi.org/10.5281/zenodo.10899862</p> <p> Digital Identification Number: IMJH-MAR-2024-2</p>	01-04

Management Approach to a Patient with Borderline Personality Disorder, Trichotillomania, and Alcohol Dependence Syndrome: Use of Endoxifen

Yogesh Avinash Kulkarni

Aastha Hospital, Station Road, Kolhapur, Maharashtra, India 416003

Received:- 6 March 2024/ Revised:- 17 March 2024/ Accepted: 24 March 2024/ Published: 31-03-2024

Copyright © 2024 International Multispecialty Journal of Health

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted Non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract— Borderline personality disorder (BPD) and alcohol abuse are both associated with impulsivity, while patients with trichotillomania demonstrate higher rates of co-morbid impulsive disorders. Impulsivity stems from overactive protein kinase C (PKC), and thus, targeting PKC can treat impulsivity. This case describes the effectiveness of endoxifen, a direct PKC inhibitor, in a patient with co-morbid BPD, alcohol dependence syndrome, and trichotillomania. There was reduced impulsivity and a motivation to cease alcohol consumption with endoxifen treatment. The patient transitioned from reluctance to disulfiram treatment to a willingness to take disulfiram. This case report adds valuable knowledge on the potential of endoxifen for patients with BPD and alcohol abuse.

Keywords— *borderline personality disorder, endoxifen, protein kinase C, substance abuse, trichotillomania.*

I. INTRODUCTION

Impulsivity is a core feature of borderline personality disorder (BPD), and manifests as irresponsible behavior, problematic substance abuse, self-harm, and disordered eating, which thus impact quality-of-life. The high-trait impulsivity characteristic of BPD patients involves rapid and unplanned behaviors.¹ Trichotillomania was earlier classified as an impulse control disorder (involving an impaired ability to resist impulses to engage in ultimately self-destructive behavior), though it is now classified under obsessive-compulsive disorders. However, a higher prevalence rate of co-morbid impulsive disorders and alcohol use disorders has been reported in this population.² Impulsivity is reported to arise from overactivity of protein kinase C (PKC), suggesting that PKC can be a treatment target.^{3,4}

The case study described in this report demonstrates the use of endoxifen in a patient with BPD, trichotillomania, and alcohol dependence syndrome, who was not responsive to multiple therapies. The use of endoxifen, a direct PKC inhibitor, along with other antipsychotics led to symptomatic improvement, and the resulting reduction in impulsivity prompted a motivation to reduce alcohol consumption.

II. CASE REPORT

A 22-year-old female presented with alcohol dependence syndrome, trichotillomania, and borderline personality disorder (BPD). Initial symptoms were noted approximately three years prior to the commencement of treatment. The patient had been under the care of another psychiatrist for 2 months, and the treatment did not lead to significant improvement. Previous interventions included lithium (400 mg twice-daily), aripiprazole (7.5 mg once-daily), and fluvoxamine (50 mg twice-daily) along with clonazepam (0.5 mg as required for sleep management) for two months. A total of six sessions of electroconvulsive therapy (ECTs) were also administered.

Upon presentation to the clinic, the patient's treatment plan was revised. Initial medications were discontinued, and lamotrigine was initiated at a dose of 25 mg twice-daily, titrated up to 100 mg twice-daily over 6-8 weeks. Ziprasidone (20 mg at night) and sertraline (100 mg, uptitrated to 150 mg once-daily) were prescribed for two months. Despite marginal improvement in symptoms of BPD, alcohol dependence and trichotillomania persisted. The Borderline Evaluation of Severity over Time (BEST) score was 68 (out of a maximum score of 70), and moderate-severe alcohol use disorder.

TABLE 1
COMPARISON OF BEST SCORE AND AUDIT SCORE BEFORE AND AFTER TREATMENT WITH ENDOXIFEN

BORDERLINE EVALUATION OF SEVERITY OVER TIME (BEST)	Before endoxifen	After endoxifen
A: Thoughts and feelings	(31)	(14)
Worrying that someone important in your life is tired of you or is planning to leave you	4	1
Major shifts in your opinions about others such as switching from believing someone is a loyal friend or partner to believing the person is untrustworthy and hurtful	4	3
Extreme changes in how you see yourself. Shifting from feeling confident about who you are to feeling like you are evil or that you don't even exist	3	2
Severe mood swings several times a day. Minor events cause major shifts in moods	5	2
Feeling paranoid or like you are losing touch with reality	3	2
Feeling angry	4	1
Feelings of emptiness	4	1
Feeling suicidal	4	2
B: Behaviors (negative)	(18)	(7)
Going to extremes to try to keep someone from leaving you	5	3
Purposefully doing something to injure yourself or making a suicide attempt	4	1
Problems with impulsive behavior (not counting suicide attempts or injuring yourself on purpose). Examples include: over-spending, risky sexual behavior, substance abuse, reckless driving, binge eating, other	5	1
Temper outbursts or problems with anger leading to relationship problems, physical fights, or destruction of property	4	2
C: Behaviors (positive)	(4)	(10)
Choosing to use a positive activity in circumstances where you felt tempted to do something destructive or self-defeating	1	3
Noticing ahead of time that something could cause you emotional difficulties and taking reasonable steps to avoid/prevent the problem	2	3
Following through with therapy plans to which you agreed (e.g., talk therapy, homework assignments, coming to appointments, medications, etc.)	1	4
ALCOHOL USE DISORDERS IDENTIFICATION TEST (AUDIT)	Before endoxifen	After endoxifen
1. How often do you have a drink containing alcohol?	4 (4 or more times a week)	1 (Monthly or less)
2. How many drinks containing alcohol do you have on a typical day when you are drinking?	0 (1 or 2)	0 (1 or 2)
3. How often do you have six or more drinks on one occasion?	0 (Never)	0 (Never)
4. How often during the last year have you found that you were not able to stop drinking once you had started?	4 (Daily or almost daily)	1 (Less than monthly)
5. How often during the last year have you failed to do what was normally expected from you because of drinking?	4 (Daily or almost daily)	4 (Never)
6. How often during the last year have you needed a first drink in the morning to get yourself going after a heavy drinking session?	4 (Daily or almost daily)	1 (Less than monthly)
7. How often during the last year have you had a feeling of guilt or remorse after drinking?	4 (Daily or almost daily)	1 (Less than monthly)
8. How often during the last year have you been unable to remember what happened the night before because you had been drinking?	4 (Daily or almost daily)	0 (Never)
9. Have you or someone else been injured as a result of your drinking?	0 (No)	NA
10. Has a relative or friend or a doctor or another health worker been concerned about your drinking or suggested you cut down?	0 (Yes, during the last year)	NA
<p>AUDIT: Alcohol Use Disorders Identification Test; BEST: Borderline Evaluation of Severity over Time. NA: Not applicable; questions 9 and 10 of the AUDIT were Not Applicable as the total score for questions 2 and 3 was 0. For the BEST scale, total composite score is calculated as 15 + A + B + C.</p>		

The patient was unwilling to take disulfiram due to the desire to engage in social drinking. Ziprasidone was discontinued, sertraline (150 mg once-daily) and lamotrigine (100 mg twice-daily) were continued, and endoxifen (8 mg once-daily) was prescribed. After six weeks, the patient demonstrated significant improvement in trichotillomania and alcohol abuse. Subsequently, she was motivated to start disulfiram therapy (250 mg once-daily), as Endoxifen helped reduce her impulsivity to engage in drinking. Endoxifen was continued at 8 mg once-daily, sertraline was downtitrated to 100 mg once-daily from 150 mg and lamotrigine was downtitrated to 100 mg once-daily from 100 mg twice-daily. The patient responded positively to the prescribed treatment. Trichotillomania symptoms decreased significantly, and the patient was motivated to cease alcohol consumption. Endoxifen was continued at 8 mg once-daily, along with sertraline (100 mg once-daily) and lamotrigine (100 mg once-daily).

After 12 weeks of Endoxifen treatment, the BEST score was 46 (out of a maximum score of 70), and the AUDIT score was 4 (low-risk consumption). Table 1 describes the change in scores for the individual components of the BEST and AUDIT tools. The patient is currently alcohol-free, with no trichotillomania symptoms, and has experienced a significant reduction in BPD symptoms (mood swings, anger, suicidal thoughts, self-harm, and impulsive behaviors reduced). Alcohol consumption reduced from 4 times a week to no alcohol, and the patient no longer needed to drink alcohol in the morning, compared to daily/almost daily consumption of alcohol in the morning). Body weight decreased from 94 kg to 80 kg during treatment. The patient continued regular follow-up visits, and Endoxifen was administered for a total duration of six months, with no adverse effects reported.




FIGURE 1: Comparison of (A) BEST score and (B) AUDIT score before and after endoxifen treatment

AUDIT: Alcohol Use Disorders Identification Test; BEST: Borderline Evaluation of Severity over Time.

For the BEST scale, total composite score is calculated as $15 + A + B + C$.

III. DISCUSSION

The case described in this report highlights the use of endoxifen for the management of BPD, alcohol abuse, and trichotillomania, all of which are known to be associated with impulsivity. Targeting PKC overactivity as a cause of impulsivity led to a reduction in symptoms of BPD as well as trichotillomania. Furthermore, the patient transitioned from wanting to consume alcohol to being motivated to cease alcohol consumption.

Impulsivity has been linked to future alcohol use disorders, and conversely, heavy alcohol use can lead to impulsive behaviors through weakened self-regulation.⁵ In addition, alcohol is reported to increase PKC isozyme levels or reduce the degradation of membrane-bound PKC isozymes.⁴ Addictive behavior can stem from redistribution of PKC in different brain regions following ethanol exposure.⁶ Therefore, drugs targeting PKC can reduce alcohol abuse.⁴ PKC overactivity can be reduced through a PKC inhibitor such as endoxifen. Endoxifen can inhibit PKC by up to 78%⁷ and has a good safety profile with a low rate of treatment discontinuation due to adverse effects.^{8,9}

The anti-manic effect has been demonstrated in clinical trials,^{8,9} and the expanded scope of use for the management of BPD, impulsivity disorders, and substance abuse has been described through recent case reports.¹⁰⁻¹² In consonance with a previous report by Banerjee and Ray,¹¹ endoxifen treatment of BPD led to improvement in BEST scores and curbed substance abuse.

In this case, the patient did not respond to treatment with lithium, aripiprazole, and fluvoxamine. Lamotrigine, ziprasidone, and sertraline led to partial improvement of BPD, but alcohol abuse and trichotillomania persisted until endoxifen was initiated. The resulting reduction in impulsivity translated into a reduced alcohol craving. The patient was then amenable to disulfiram

treatment for alcohol abuse. Therefore, endoxifen not only reduced impulsivity and BPD symptoms, but also permitted improved management of co-morbid alcohol abuse. This impact can be of particular benefit to patients with comorbid BPD and alcohol abuse, which are known to co-exist.

IV. CONCLUSION

This case report describes the impact of endoxifen treatment in a patient with co-morbid BPD, alcohol dependence syndrome, and trichotillomania, all of which are known to be linked to impulsivity. Impulsivity is mediated by PKC overactivity, and endoxifen is a direct PKC inhibitor with known anti-manic action. The patient responded well to endoxifen as part of combination therapy. The addition of endoxifen led to reduced symptoms of BPD, trichotillomania, and alcohol abuse, and the patient was subsequently motivated to stop consuming alcohol and take up treatment with disulfiram. The key action of reducing impulsivity thus had an extended impact on the range of comorbid conditions in this patient. This case report adds to the pool of literature and enhances our knowledge of this molecule for the management of psychiatric conditions.

REFERENCES

- [1] Lawrence KA, Sabura Allen J, Chanen AM. Impulsivity in borderline personality disorder: reward-based decision-making and its relationship to emotional distress. *J Personality Disord.* 2010;24(6):786–99. <https://guilfordjournals.com/doi/10.1521/pedi.2010.24.6.785>.
- [2] Grant JE, Collins M, Chamberlain SR, Chesivior E. Disorders of impulsivity in trichotillomania and skin picking disorder. *J Psychiatr Res.* 2024;170:42–6. <https://www.sciencedirect.com/science/article/abs/pii/S0022395623005757>.
- [3] Birnbaum SG, Yuan PX, Wang M, Vijayraghavan S, Bloom AK, Davis DJ, et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. *Science.* 2004;306(5697):882–4. <https://www.science.org/doi/abs/10.1126/science.1100021>.
- [4] Newton PM, Ron D. Protein kinase C and alcohol addiction. *Pharmacol Res.* 2007;55(6):570–7. <https://www.sciencedirect.com/science/article/abs/pii/S1043661807000874>.
- [5] Dick DM, Smith G, Olausson P, Mitchell SH, Leeman RF, O'Malley SS, et al. Understanding the construct of impulsivity and its relationship to alcohol use disorders. *Addict Biol.* 2010;15(2):217–26. <https://onlinelibrary.wiley.com/doi/10.1111/j.1369-1600.2009.00190.x>.
- [6] Mohammed RMP, Mokhtar MH, Yap E, Hanim A, Wahab NA, Jaffar FHF, et al. Ethanol-induced changes in PKC ϵ : From cell to behavior. *Front Neurosci.* 2018;12(12):244. <https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2018.00244/full>.
- [7] Ali SM, Ahmad A, Shahabuddin S, Ahmad MU, Sheikh S, Ahmad I. Endoxifen is a new potent inhibitor of PKC: a potential therapeutic agent for bipolar disorder. *Bioorg Med Chem Lett.* 2010;20:2665–7. <https://www.sciencedirect.com/science/article/abs/pii/S0960894X10002143>.
- [8] Ahmed A, Sheikh S, Shah T, Reddy MS, Prasad BSV, Verma KK, et al. Endoxifen, a new treatment option for mania: A double-blind, active-controlled trial demonstrates the antimanic efficacy of endoxifen. *Clin Translational Sci.* 2016;9(5):252–9. <https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12407>.
- [9] Ahmed A, Sheikh S, Khan MA, Chaturvedi A, Patel P, Patel R, et al. Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder. *Bipolar Disorders.* 2021;23(6):595–603. <https://onlinelibrary.wiley.com/doi/10.1111/bdi.13041>.
- [10] Dave M, Shanmugasundaram N. Endoxifen for the management of bipolar disorder with comorbid substance use disorder: A report of two cases. *Arch Biol Psychiatr.* 2023;1(1):25–8. <https://archivesbiologicalpsychiatry.org/endoxifen-for-the-management-of-bipolar-disorder-with-comorbid-substance-use-disorder-a-report-of-two-cases/>.
- [11] Banerjee D, Ray R. Endoxifen in treatment of individuals with borderline personality disorder with predominant impulsivity: A case series. *Consortium Psychiatricum.* 2023; 2023;4(4):CP13622. <https://consortium-psy.com/jour/article/view/13622>.
- [12] Tharoor H. End of craving with endoxifen in substance use & bipolar disorder. *J Clin Pharmacol Ther.* 2023;4(3):1048. <https://www.medtextpublications.com/open-access/end-of-craving-with-endoxifen-in-substance-use-amp-bipolar-1498.pdf>.

The background of the page is a dark red color with a light red grid pattern. In the center, there is a large, faint, light red caduceus symbol. To the left and right of the caduceus, there are faint, light red ECG (heart rate) lines. The overall design is clean and professional, typical of a medical journal or publication cover.

AD Publications

Sector-3, MP Colony, Bikaner, Rajasthan, INDIA

www.adpublications.org, www.imjhealth.org, info@imjhealth.org